DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia

Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: Imatinib (Gleevec) (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: University Health Network, Toronto


This is a Phase I-II study evaluating the toxicity and efficacy of imatinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy in relapsed and refractory AML. Patients will be treated initially at a 200 mg dose of imatinib; if tolerated, the imatinib dose will be escalated in subsequent cohorts to 300 mg and 400 mg. Once the recommended dose is determined, the remaining patients will be treated at that dose, to evaluate the antileukemic activity of the regimen. Patients achieving complete remission will receive consolidation therapy with imatinib combined with high-dose cytarabine and mitoxantrone, followed by maintenance imatinib.

Clinical Details

Official title: A Phase I-II Study Evaluating the Safety and Efficacy of Imatinib Mesylate (Gleevec) Combined With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive Acute Myeloid Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Toxicity (hematologic and non-hematologic) of the combination of Imatinib and Chemotherapy consisting of Mitoxantrone, Etoposide and Ara-c

Response rate - CR, MLFS and PR as per section 7.1

Maximum tolerated dose of Imatinib when given in combination with chemotherapy

Secondary outcome:

Toxicity of imatinib maintenance therapy.

Number of Participants with adverse events as a measure of safety and tolerability

Remission-free survival and overall survival.

Total and phosphorylated c-kit activity at Days 1 and 4.

Levels of downstream components of c-kit pathway at Days 1 & 4.

Detailed description: Induction therapy:

- Imatinib 200-400 mg p. o. daily x 10 days, Days 1-10 (see dose escalation scheme in

Section 5. 4 below).

- Mitoxantrone 10 mg/m2 daily x 5 days, Days 4-8.

- Etoposide 100 mg/m2 daily x 5 days, Days 4-8.

- Cytarabine 1. 5 grams/m2 q12h x 4 doses, Days 9-10 (for patients aged 60 years and over,

1. 0 gram/m2). Only one induction course will be permitted. Only patients achieving CR will proceed to consolidation and maintenance. Consolidation therapy, maximum 2 cycles (for patients achieving CR):

- Imatinib 200-400 mg p. o. daily x 8 days, Days 1-8 (see dose escalation scheme in

Section 5. 4 below).

- Mitoxantrone 12 mg/m2 daily x 2 days, Days 4-5.

- Cytarabine 3 grams/m2 q12h x 6 doses, Days 4,6,8. For patients aged 60 years and over,

the dose will be reduced to 1. 5 grams/m2. Maintenance therapy (for patients still in CR at end of consolidation): Imatinib 600 mg p. o. daily, until relapse or toxicity (see dose modification criteria in Section 5. 6.6 below). Patients must receive at least one consolidation cycle before being permitted to proceed to maintenance therapy (see Section 5. 6 for details). Maintenance therapy with imatinib will be provided for a maximum period of 1 year. Dose escalation scheme: Imatinib will be used during induction and consolidation at one of the following dose levels:

Level - 1 100 mg daily Level 1 200 mg daily Level 2 300 mg daily Level 3 400 mg daily


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- AML, all subtypes except APL.

- Prior induction therapy consisting of cytarabine 100-200 mg/m2 plus an anthracycline.

- One of the following:

- persistent leukemia after induction therapy.

- relapse within two years of achieving complete remission with induction therapy.

Any consolidation therapy is acceptable, including stem cell transplantation.

- At least 10% bone marrow blasts, or biopsy confirmed extramedullary disease.

- Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry.

- Aged 18-65.

- ECOG performance status < 3 (see Appendix I).

- No chemotherapy within the previous four weeks, other than hydroxyurea to control

counts. If hydroxyurea is used, it must be stopped at least 24 hours prior to starting imatinib.

- Able to given informed consent.

Exclusion Criteria:

- Active uncontrolled infection.

- Active CNS leukemia.

- Serum creatinine > 200 umol/L.

- Serum bilirubin > 1. 5 x ULN, AST or ALT > 2x ULN.

- Left ventricular ejection fraction < 50%.

Locations and Contacts

Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada
Additional Information

Starting date: July 2004
Last updated: June 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017